Chitosan-based matrices and uses thereof

Abstract

This invention relates a controlled release delivery composition for an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination, using a chitosan-glycerophosphate (CGP) hydrogel and an agent or a bio-materials. Additionally, provided methods of treating an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination.

1 . A composition for controlled release delivery, comprising: a chitosan-glycerophosphate (CGP) hydrogel; and one or more agent effective in the treatment of otorhinolaryngology-associated pathology, or Head and Neck associated pathology. 
     
     
         2 . The composition of  claim 1 , wherein said composition comprises 2-10% (w/w) chitosan. 
     
     
         3 . The composition of  claim 1 , wherein said composition comprises 5-30% (w/w) glycerophosphate. 
     
     
         4 . The composition of  claim 1 , wherein said composition is in a gel form. 
     
     
         5 . The composition of  claim 1 , wherein the agent is an active pharmaceutical ingredient. 
     
     
         6 . The composition of  claim 5 , wherein the releases of said active pharmaceutical ingredient is over a period of no less than 24 hours. 
     
     
         7 . The composition of  claim 5 , whereby the controlled release rate is adjusted by varying a ratio of chitosan to glycerophosphate components. 
     
     
         8 . The composition of  claim 7 , wherein, when the agent is hydrophilic, the higher the ratio of chitosan to glycerophosphate, the longer is the agent release following the initial release. 
     
     
         9 . The composition of  claim 7 , wherein, when the agent is hydrophobic, the lower the ratio of chitosan to glycerophosphate, the longer is the agent release following the initial release. 
     
     
         10 . The controlled release composition of  claim 1 , wherein the chitosan-glycerophosphate (CGP) hydrogel is comprised of a chitosan-glycerophosphate (CGP) hydrogel having a first chitosan to glycerophosphate ratio; and a chitosan-glycerophosphate (CGP) hydrogel having a second chotosan to glycerophosphate ratio, wherein the first chitosan to glycerophosphate ratio is different from the second chotosan to glycerophosphate ratio 
     
     
         11 . The composition of  claim 1 , wherein said one or more agent is steroids, antibiotics, other drugs, gene and molecular therapeutical agents or their combination. 
     
     
         12 . A method of treating an otorhinolaryngology-associated pathology, or Head and Neck associated pathology in a subject, comprising the step of inserting a composition comprising a chitosan-glycerophosphate (CGP) hydrogel and one or more agent in a predetermined region of said subject, wherein the agent is effective in the treatment of otorhinolaryngology-associated pathology, or Head and Neck associated pathology. 
     
     
         13 . The method of  claim 12 , whereby said composition comprises 2-10% (w/w) chitosan. 
     
     
         14 . The method of  claim 12 , whereby said composition comprises 5-30% (w/w) glycerophosphate. 
     
     
         15 . The method of  claim 12 , whereby said composition is in a gel form. 
     
     
         16 . The method of  claim 12 , whereby said composition is a controlled release composition. 
     
     
         17 . The method of  claim 16 , whereby said composition releases said active pharmaceutical ingredient over a period of no less than 24 hours. 
     
     
         18 . The method of  claim 16 , whereby a release profile is adjusted by varying a ratio of chitosan to glycerophosphate macromonomers. 
     
     
         19 . The method of  claim 18 , whereby, when the agent is hydrophilic, the higher the ratio of chitosan to glycerophosphate macromonomers, the longer is the agent release following the initial release. 
     
     
         20 . The method of  claim 18 , whereby, when the agent is hydrophobic, the lower the ratio of chitosan to glycerophosphate macromonomers, the longer is the agent release following the initial release. 
     
     
         21 . The method of  claim 12 , whereby the chitosan-glycerophosphate (CGP) hydrogel is comprised of a chitosan-glycerophosphate (CGP) hydrogel having a first chotosan to glycerophosphate macromonomers ratio; and a chitosan-glycerophosphate (CGP) hydrogel having a second chotosan to glycerophosphate macromonomers ratio, wherein the first chitosan to glycerophosphate macromonomers ratio is different from the second chotosan to glycerophosphate macromonomers ratio. 
     
     
         22 . The method of  claim 12 , whereby the predetermined region is the regions of ear, nose, throat, head and neck. 
     
     
         23 . The method of  claim 12 , whereby the Otorhinolaryngology-associated pathology includes the diseases of otology, neurotology, rhinology, allergy, laryngology, bronchoesophagology, head and neck.